NOT JUST ANY SOLUTION
OXERVATE® is the only FDA-approved treatment option to enable complete corneal healing in most patients with NK.*1-3
OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment.1
Resolution was evaluated in clinical trials as complete corneal healing, defined as the absence of staining in the lesion area and no persistent staining in the rest of the cornea after 8 weeks of treatment and as <0.5-mm lesion staining at 48-week follow-up.1-3
for patients with NK1
course of therapy1
single point of contact
About NK
NK is caused by corneal nerve damage4
Corneal nerve damage may lead to a decrease in or total loss of corneal sensitivity—the hallmark of neurotrophic keratitis (NK).5
This impairment in corneal innervation and sensitivity can then lead to epithelial breakdown in the cornea.5
OXERVATE MOA
A unique mechanism of action that targets corneal nerve damage, the underlying cause of NK1,4,6,7
Cenegermin-bkbj, the active ingredient in OXERVATE, is a recombinant form of human nerve growth factor (rhNGF).1
NGF is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (ie, TrkA) and low-affinity (ie, p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.1
Efficacy & Safety
The efficacy and safety of OXERVATE® were established in the largest clinical trial program conducted in patients with NK1
In clinical trials, up to
of patients achieved complete corneal healing at week 8
with a single course of therapy*†1-3
Of these patients in REPARO (Study NGF0212),
remained
completely healed
at 1 year*8
Complete corneal healing was defined as the absence of staining in the lesion area and no persistent staining in the rest of the cornea after 8 weeks of treatment and as <0.5-mm lesion staining at 48-week follow-up.1-3
Key study findings were after 8 weeks of treatment, 6 times daily. REPARO (Study NGF0212): 52 patients with Stage 2 or 3 neurotrophic keratitis (NK) in 1 eye per group; 72% (36/50) of patients completely healed; vehicle response rate 33.3% (17/51). Study NGF0214: 24 patients with Stage 2 or 3 NK in 1 or both eyes per group; 65.2% (15/23) completely healed; vehicle response rate 16.7% (4/24). Last post-baseline observation carried forward; chi-squared test. Patients without any post-baseline measurements were excluded from the analysis.1-3
In clinical trials, OXERVATE was generally well tolerated2,3
The most common adverse reaction was eye pain following instillation, which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs.1
Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.1
Access support and more through a single point of contact
Dompé CONNECT to Care provides practices and patients with assistance every step of the way.